-
-
CHICAGO, Illinois The U.S. introduction of drug-eluting stents, made possible by the FDAs late-April approval of the Cypher stent from Johnson & Johnsons (New Brunswick, New Jersey) Cordis (Miami Lakes, Florida) unit, will open a new chapter in the history of interventional cardiology and drive significant changes in medical practice as well as in market share for suppliers.
-
As expected, the Cypher drug-eluting coronary stent from Johnson & Johnson (New Brunswick, New Jersey) subsidiary Cordis (Miami Lakes, Florida) is the first to market in the U.S. after receiving FDA approval late last month.
-
A short exposure to a specific combination of two growth factors may be all it takes to stimulate the growth of new blood vessels that persist indefinitely, a new study suggests.
-
The traditionally deliberative FDA apparently thinks a cryotherapy system developed by CryoCath Technologies (Kirkland, Quebec), which uses extremely cold temperatures to treat diseased tissue, is a hot commodity, granting the product an approval about five months ahead of schedule, an almost unheard-of feat for the agency.
-
While many home health patients may accept pain as a normal part of their condition or of their age, it doesnt have to be that way, according to experts interviewed by Hospital Home Health.
-
Youve got a great idea for a new program, but you dont have the cash to fund the start-up expenses or maintain it while you build it. There may be grant money with your name on it you just have to use the right approach.
-
CMS evaluates PET scans for Alzheimers; Home care has positive effect on heart patients
-
This is the first in a periodic series that addresses recruitment and retention issues with examples of how home health agencies are meeting the challenge of finding and keeping good employees.
-
With more than 7,500 suspected and probable cases worldwide and 573 deaths, according the the World Health Organization, as we go to press, severe acute respiratory syndrome (SARS) has been in the news for many months.
